{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:05:53Z","timestamp":1791925553770,"version":"4.3.4"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Clopidogrel is frequently used in patients with ischemic stroke or transient ischemic attack (TIA), but its efficacy is hampered by inter-individual variability, due to genetic differences associated with clopidogrel metabolism. We conducted this randomized controlled trial to validate whether the personalized antiplatelet therapy based on clopidogrel pharmacogenomics and clinical characteristics leads to better clinical outcomes compared with standard treatment.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Patients were randomly divided into the standard group or pharmacogenetic group, in which the pharmacogenetic group required the detection of the genotyping of <jats:italic>CYP2C19*2<\/jats:italic>, <jats:italic>CYP2C19*3<\/jats:italic>, and <jats:italic>CYP2C19*17<\/jats:italic>. Patients were followed up for 90\u00a0days for the primary efficacy endpoint of new stroke events, secondary efficacy endpoint of individual or composite outcomes of the new clinical vascular events, and the incidence of disability. The primary safety outcome was major bleeding.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 650 patients underwent randomization, among which 325 were in the pharmacogenomics group while 325 were in the standard group. Our study found after a 90-day follow-up, the risk of stroke and composite vascular events in the pharmacogenomics group was lower than that in the standard group. The incidence of disability significantly decreased in the pharmacogenomics group. In addition, no statistically significant differences were observed in bleeding events between the two groups.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The present study demonstrates that personalized antiplatelet therapy guided by clopidogrel pharmacogenomics and clinical characteristics can significantly improve the net clinical benefit of ischemic stroke or TIA patients during the 90-day treatment period without increasing bleeding risk.<\/jats:p>","DOI":"10.3389\/fphar.2022.931405","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T05:20:14Z","timestamp":1674019214000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Personalized antiplatelet therapy guided by clopidogrel pharmacogenomics in acute ischemic stroke and transient ischemic attack: A prospective, randomized controlled trial"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaoguang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xushen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuming","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhua","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1056\/NEJMoa1412981","article-title":"One-year risk of stroke after transient ischemic attack or minor stroke","volume":"374","author":"Amarenco","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jcin.2017.07.022","article-title":"Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention","volume":"11","author":"Cavallari","year":"2018","journal-title":"JACC. Cardiovasc. Interv."},{"key":"B3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study","volume":"373","author":"Collet","year":"2009","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1136\/bmj.37991.635266.44","article-title":"Population based study of early risk of stroke after transient ischaemic attack or minor stroke: Implications for public education and organisation of services","volume":"328","author":"Coull","year":"2004","journal-title":"BMJ"},{"key":"B5","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41569-021-00549-w","article-title":"Pharmacogenetics to guide cardiovascular drug therapy","volume":"18","author":"Duarte","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.amjcard.2008.11.048","article-title":"Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis","volume":"103","author":"Giusti","year":"2009","journal-title":"Am. J. Cardiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1016\/S0140-6736(17)31075-9","article-title":"Adverse events associated with unblinded, but not with blinded, statin therapy in the anglo-scandinavian cardiac outcomes trial-lipid-lowering arm (ASCOT-LLA): A randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase","volume":"389","author":"Gupta","year":"2017","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/atm.2019.10.111","article-title":"Proposed antithrombotic strategy for acute ischemic stroke with large-artery atherosclerosis: Focus on patients with high-risk transient ischemic attack and mild-to-moderate stroke","volume":"8","author":"Hou","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1916870","article-title":"Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA","volume":"383","author":"Johnston","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/ijs.12129","article-title":"Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: Rationale and design","volume":"8","author":"Johnston","year":"2013","journal-title":"Int. J. Stroke"},{"key":"B11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ccd.28075","article-title":"Personalized antiplatelet therapy in patients with coronary artery disease undergoing percutaneous coronary intervention: A network meta-analysis of randomized clinical trials","volume":"94","author":"Kheiri","year":"2019","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"B12","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/cpt.2526","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update","volume":"112","author":"Lee","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.cjca.2017.12.012","article-title":"2018 Canadian cardiovascular society\/Canadian association of interventional cardiology focused update of the guidelines for the use of antiplatelet therapy","volume":"34","author":"Mehta","year":"2018","journal-title":"Can. J. Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/j.jacc.2018.02.029","article-title":"Pharmacogenomic approach to selecting antiplatelet therapy in patients with acute coronary syndromes: The PHARMCLO trial","volume":"71","author":"Notarangelo","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/CIRCULATIONAHA.116.024913","article-title":"Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: A systematic review and meta-analysis","volume":"135","author":"Pan","year":"2017","journal-title":"Circulation"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e007811","DOI":"10.1161\/CIRCINTERVENTIONS.119.007811","article-title":"Clopidogrel pharmacogenetics","volume":"12","author":"Pereira","year":"2019","journal-title":"Circ. Cardiovasc. Interv."},{"key":"B18","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Subcommittee on Control of Anticoagulation of the, T Standardization Committee of the International Society on, HaemostasisDefinition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"B19","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/FJC.0000000000000337","article-title":"Clinical value of CYP2C19 genetic testing for guiding the antiplatelet therapy in a Chinese population","volume":"67","author":"Shen","year":"2016","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/j.jacc.2007.07.058","article-title":"Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes","volume":"50","author":"Storey","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"l2211","DOI":"10.1136\/bmj.l2211","article-title":"Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: Open label, blinded endpoint, randomised controlled phase II trial","volume":"365","author":"Wang","year":"2019","journal-title":"BMJ"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1056\/NEJMoa2111749","article-title":"Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA","volume":"385","author":"Wang","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/ana.25535","article-title":"Efficacy of clopidogrel for stroke depends on CYP2C19 genotype and risk profile","volume":"86","author":"Xu","year":"2019","journal-title":"Ann. Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"649056","DOI":"10.3389\/fneur.2021.649056","article-title":"Impact of platelet endothelial aggregation receptor-1 genotypes on long-term cerebrovascular outcomes in patients with minor stroke or transient ischemic attack","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e028595","DOI":"10.1136\/bmjopen-2018-028595","article-title":"Personalised antiplatelet therapy based on pharmacogenomics in acute ischaemic minor stroke and transient ischaemic attack: Study protocol for a randomised controlled trial","volume":"9","author":"Zhang","year":"2019","journal-title":"BMJ Open"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.931405\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T05:20:16Z","timestamp":1674019216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.931405\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":26,"alternative-id":["10.3389\/fphar.2022.931405"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.931405","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]},"article-number":"931405"}}